Abstract
Ocrelizumab is a monoclonal antibody commonly used in the treatment of multiple sclerosis (MS). Hypersensitivity reactions to ocrelizumab have been reported in up to 5.6 % in non-African American patients. To date, non-irritating skin testing concentrations for ocrelizumab have not yet been established. We present a patient with negative skin testing (ST) and a negative drug provocation test (DPT) to ocrelizumab.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call